Adalimumab Biosimilar May Reduce Antibody Response After COVID-19 Vaccine

SARS-CoV-2 antibody levels did not change significantly in patients receiving originator adalimumab, while patients receiving the biosimilar experienced a significant decrease.

Related Keywords

Czech Republic , ,Drug Administration ,Masaryk University ,Masaryk University David Vetch ,David Vetch ,Drug Evaluation ,Accessed February ,